Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 21.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,649 shares of the company’s stock after buying an additional 3,312 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Disc Medicine were worth $916,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IRON. Amalgamated Bank increased its position in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Disc Medicine in the 2nd quarter valued at approximately $129,000. Quest Partners LLC purchased a new stake in Disc Medicine in the third quarter valued at approximately $131,000. Finally, Quantbot Technologies LP acquired a new position in Disc Medicine during the third quarter worth $146,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 12,791 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William Richard White sold 7,136 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,627 shares of company stock worth $2,883,150. Corporate insiders own 4.24% of the company’s stock.

Disc Medicine Stock Performance

IRON stock opened at $63.50 on Thursday. The company’s 50 day moving average price is $58.19 and its 200 day moving average price is $50.24. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -15.95 and a beta of 0.76. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. Equities analysts forecast that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research report on Monday, December 9th. Wedbush reissued an “outperform” rating and set a $83.00 price target on shares of Disc Medicine in a research report on Monday, December 9th. Stifel Nicolaus raised their price objective on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. Finally, Wells Fargo & Company started coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price on the stock. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $87.50.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.